Beg to differ JTG but continuous reporting of results from the OLE will provide a catalyst for further price appreciation. Not only that but results of MPL testing for other neurodegenerative diseases will surely provide strong SP support. We also the MPL liquid formulation, IND, patient enrollment and first dosing of >200 patients to provide a SP kicker.
Together with worldwide investor exposure provided by acceptance to Healey PAA will be on the radar of the big players so I do see significant SP upside in the next 12 months
Can BP allow such developments without commencing M&A activity, I doubt it
Ann: Investor Briefings & Webinar Notice, page-75
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.005(3.03%) |
Mkt cap ! $82.65M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.8¢ | $151.1K | 877.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 54714 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 371375 | 7 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |